Oxeia Biopharma
About
Oxeia Biopharma is pioneering the first potential FDA-approved concussion treatment using proprietary ghrelin therapy (OXE103). Funding supports Phase 2b clinical development. Recent trials showed promising results for treating persistent concussion symptoms.
AI Investment Summary
Oxeia is developing the first potential FDA-approved concussion treatment. The concussion treatment market is largely unaddressed — 3.8M sports concussions annually in the US alone. Phase 2b funding raises the stakes and the potential.
Structure
Direct Equity
Stage
Series A
Accreditation
Open to All
Liquidity
Illiquid
Geography
United States
Revenue
pre revenue
Funding Progress
55%Total Investors
1,500
Green Flags
- No FDA-approved concussion treatment exists
- 3.8M annual concussions in US alone
- Promising Phase 2b results
- $50M valuation is reasonable for clinical-stage biotech
Risk Flags
- Pre-revenue biotech
- FDA clinical trial risk — Phase 2b
- Biotech failure rate is ~90%
- Capital-intensive drug development
Similar Deals in Biotech & Pharma
Rexis Biotech
Seed
Biotech ingredients improving supplement absorption — $14.7M projected revenue.
Min. Investment
$100
Funded
45%
Aarvik Therapeutics
Seed
Reengineering life-saving injections — $3M+ raised, top Wefunder campaign.
Min. Investment
$100
Minimum Investment
$500
Valuation
$50M
Lock-up Period
5 years
Tags
LISTED
2026-02-01